Form 4: Bristol-Myers Squibb Director Derica W. Rice Acquires Deferred Share Units

Director Derica W. Rice acquired 663.013 deferred share units of Bristol-Myers Squibb on December 31, 2024, which will convert to common stock upon settlement.

Summary

• On December 31, 2024, Derica W. Rice, a director at Bristol-Myers Squibb, acquired 663.013 deferred share units.
• These deferred share units will convert into shares of common stock upon settlement.
• The settlement of these units will occur when Mr. Rice ceases to be a director or at a previously specified future date.
• The price of the deferred share units was $56.56 each.
• Following this transaction, Mr. Rice beneficially owns 26,841.243 deferred share units.
• This total includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed as neutral to slightly positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.
• The deferred share units will convert to common stock, aligning the director's interests with those of shareholders.

Future Outlook

The deferred share units will be converted into common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies. It reflects the company's compensation structure for non-employee directors.

Comparison to Industry Standards

• The use of deferred share units as part of director compensation is a common practice among large publicly traded companies, including pharmaceutical companies like Bristol-Myers Squibb.
• Companies such as Pfizer (PFE) and Merck (MRK) also utilize similar forms of equity-based compensation for their directors.
• The vesting and settlement terms, such as upon cessation of directorship, are also standard in the industry.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Deferred Share Units, Director, Beneficial Ownership, SEC Form 4, Bristol-Myers Squibb, BMY, Derica W. Rice, Stock Acquisition